Document Detail


AC133 expression associated with poor prognosis in stage II colorectal cancer.
MedLine Citation:
PMID:  23322518     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Identification of high-risk prognostic markers for stage II colorectal cancer (CRC) is currently a big challenge. CD133 is one of the most commonly used CRC stem cell markers. However, its specificity is controversial. Recent studies have demonstrated that the AC133 epitope of CD133, not the CD133 protein, is responsible for cancer stem cell identification. The aim of this study was to investigate the clinical significance of AC133 expression in stage II CRC. Two antibodies against CD133, including AC133 and Ab19898, were compared for their expression characteristics. AC133 was chosen for further immunohistochemical assessment on 176 stage II CRC primary tumors with at least 12 examined lymph nodes. The cutoff value for positive rate of AC133 expression was determined by ROC curve analysis. AC133 was analyzed for correlations with clinicopathological and prognostic parameters. The results indicated that AC133 was negative in adjacent noncancerous colorectal mucosa while positive in 116 cases (65.9 %) of primary tumors. AC133 expression was significantly correlated with preoperative serum carcinoembryonic antigen level (p = 0.006) and tumor differentiation grade (p = 0.019). Furthermore, high AC133 expression was identified as a significant predictor for poor disease-free survival and overall survival at both univariate (p = 0.009, 0.013, respectively) and multivariate levels (p = 0.022, 0.026, respectively). Our data suggest that AC133 is an independent adverse prognostic factor and a potential marker for survival classification in stage II CRC patients.
Authors:
Xiaofang Ying; Jiangxue Wu; Xiangqi Meng; Yufang Zuo; Qing Xia; Jinou Chen; Yanfen Feng; Ranyi Liu; Liren Li; Wenlin Huang
Related Documents :
2792898 - Radiation therapy for primary squamous cell carcinoma of the vagina: stanford universit...
21990228 - Evidence-based review of treatment options for patients with glottic cancer.
23636798 - The difference in clinic-pathological features between signet ring cell carcinoma and g...
24160898 - Prognostic value of isocitrate dehydrogenase 1, o6-methylguanine-dna methyltransferase ...
22882698 - Pemetrexed plus platinum or gemcitabine plus platinum for advanced non-small cell lung ...
12812848 - Hypofractionated radiotherapy for poor prognosis malignant glioma: matched pair surviva...
Publication Detail:
Type:  Journal Article     Date:  2013-01-16
Journal Detail:
Title:  Medical oncology (Northwood, London, England)     Volume:  30     ISSN:  1559-131X     ISO Abbreviation:  Med. Oncol.     Publication Date:  2013 Mar 
Date Detail:
Created Date:  2013-01-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9435512     Medline TA:  Med Oncol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  356     Citation Subset:  IM    
Affiliation:
State Key Laboratory of Oncology in South China, Cancer Center, Sun Yat-sen University, No. 651 Dongfeng East Road, Guangzhou, 510060, Guang Dong, China.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Reduced Blood Leukocyte and Neutrophil Numbers in the Pathogenesis of Type 1 Diabetes.
Next Document:  When less is better: the safety and efficacy of reduced intensity gemcitabine in a difficult patient...